Cellectar Biosciences, Inc. (CLRB)
| Market Cap | 22.69M +38.3% |
| Revenue (ttm) | n/a |
| Net Income | -22.32M |
| EPS | -3.75 |
| Shares Out | 9.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,670 |
| Open | 2.370 |
| Previous Close | 2.350 |
| Day's Range | 2.370 - 2.440 |
| 52-Week Range | 2.200 - 6.520 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+379.17%) |
| Earnings Date | Aug 13, 2026 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 cli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CLRB stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 379.17% from the latest price.
News
Cellectar Biosciences Transcript: Study update
A phospholipid ether platform enables antigen-independent, selective delivery of diverse therapeutic payloads to a wide range of cancers by targeting lipid rafts. Clinical and preclinical data show strong efficacy and tumor selectivity, with ongoing expansion into new modalities and tumor types.
Cellectar Biosciences Slides: Study update
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)
“Our second quarter marked another period of significant execution as we continued to advance multiple programs across our oncology pipeline while laying the foundation for several important near-term...
Cellectar Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 saw strong clinical and regulatory progress, highlighted by positive iopofosine data in WM, initiation of a phase III trial, and strengthened finances via a $140M financing. The company is on track for an Accelerated Approval submission in 2027 and expanding its radiopharmaceutical pipeline.
Cellectar Biosciences Quarterly report: Q2 2026
Cellectar Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cellectar Biosciences Earnings release: Q2 2026
Cellectar Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results
Cellectar Biosciences (CLRB) announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavil...
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma
Cellectar Biosciences initiated with a Buy at Brookline
Brookline initiated coverage of Cellectar Biosciences (CLRB) with a Buy rating and $15 price target
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Cellectar Biosciences Registration statement: Registration filing
Cellectar Biosciences filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences files to sell 51.21M shares of common stock for holders
17:08 EDT Cellectar Biosciences (CLRB) files to sell 51.21M shares of common stock for holders
Cellectar Biosciences Registration statement: Registration filing
Cellectar Biosciences filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences assumed with a Buy at Ladenburg
Ladenburg assumed coverage of Cellectar Biosciences (CLRB) with a Buy rating and $10 price target
Cellectar Biosciences Earnings Call Transcript: Q1 2026
Positive 12-month iopofosine data in WM and a $140M financing mark a pivotal quarter, enabling phase III trial initiation and potential accelerated FDA approval. CLR 125 advances in TNBC, with strong financial runway into 2027.
Cellectar Biosciences Quarterly report: Q1 2026
Cellectar Biosciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
Cellectar Biosciences Earnings release: Q1 2026
Cellectar Biosciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.